bullish
JHBP/Genor (嘉和生物) IPO: Undemanding Valuation with a Strong Investor Line-Up
441 Views23 Sep 2020 15:00
JHBP/Gencor Biopharmaceutical (hereafter Gencor) is a China-based biotech company with a focus on oncology and autoimmune drugs with development...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Genor Biopharma (6998 HK): First Product Approved in China; Late-Stage Pipeline Entails Visibility09 May 2022
- JHBP/Genor (嘉和生物) IPO Trading: Visible Upsides06 Oct 2020
- JHBP/Genor (嘉和生物) Pre-IPO: Thoughts on Valuation15 Sep 2020
- Genor (嘉和生物) Pre-IPO: Slow R&D Progress in the past but that Might Change19 Jul 2020
x